. Author manuscript; available in PMC: 2012 Nov 1.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 May 17;81(3):e93–e99. doi: 10.1016/j.ijrobp.2010.12.067

Table 4.

Patients with or without “complications” at ≥12 months, and their PC and GSL doses. See definition of “complications” in Methods.

		Worsened VF scores	Increased VF-based aspirations	Worsened HNQOL Eating Domain	Worsened UWQOL swallow
No. patients with ‘complications”/total assessable patients		16/58	21/67	8/59	5/60
Mean PC doses (Gy)
	Patients with “complications”	62±8	64±8	62±8	61±10
	Patients without “complications”	52±8	53±8	54±9	55±9
	p	<0.001	<0.001	0.16	0.04
Mean GSL doses (Gy)
	Patients with “complications”	48±16	53±17	54±12	40±13
	Patients without “complications”	36±12	36±12	38±14	40±15
	p	0.004	0.001	0.03	0.9

Abbreviations: NTCPs- normal tissue complications probabilities. PC- pharyngeal constrictors. GSL- glottis & supraglottic larynx. HNQOL- Head &Neck Quality of Life questionnaire. UWQOL-University of Washington Quality of Life questionnaire.